Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair

Por Wenhao Zhang, Chen-Yi Liao, Hajar Chtatou, Luca Incrocci, Dik C. van Gent, Wytske M. van Weerden, Julie Nonnekens
Publicado em 2019-10-01

The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel‐resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe

Por Stanislav Drápela, Prashant Khirsariya, Wytske M. vanWeerden, Radek Fedr, Tereza Suchánková, Diana Búzová, Jan Červený, Aleš Hampl, Martin Puhr, William R. Watson, Zoran Culig, Lumír Krejčí, Kamil Paruch, Karel Souček
Publicado em 2020-10-01

NanoBiT System and Hydrofurimazine for Optimized Detection of Viral Infection in Mice—A Novel in Vivo Imaging Platform

Por Natasa Gaspar, Giorgia Zambito, Iris J. C. Dautzenberg, Steve J. Cramer, Rob C. Hoeben, Clemens Lowik, Joel R. Walker, Thomas A. Kirkland, Thomas P. Smith, Wytske M. van Weerden, Jeroen de Vrij, Laura Mezzanotte
Publicado em 2020-08-01

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel

Por Anieta M. Sieuwerts, Wendy Onstenk, Jaco Kraan, Corine M. Beaufort, Mai Van, Bram De Laere, Luc Y. Dirix, Paul Hamberg, Aart Beeker, Hielke J. Meulenbeld, Geert‐Jan Creemers, Wytske M. vanWeerden, Guido W. Jenster, Annemieke J. M. Nieuweboer, Ron H. J. Mathijssen, Ronald deWit, John W. M. Martens, Stefan Sleijfer
Publicado em 2019-08-01